Advancements in Karyotyping & the Impact on Cell-based Research

Disease Models, iPS Cells, Editing Process | January 9, 2025 | By Travis Hardcastle
Advancements in Karyotyping & the Impact on Cell-based Research
Share

Interested in how EditCo can enable development of new cell-based disease models?

Learn More
What You Missed at AACR 2026: Five Takeaways From San Diego That Could Change Your Cell Lineup
Drug Discovery

What You Missed at AACR 2026: Five Takeaways From San Diego That Could Change Your Cell Lineup

A field report from the EditCo team

Read More
Ensuring iPSC Quality: Best Practices in Pluripotency Testing for Disease Models
iPS Cells

Ensuring iPSC Quality: Best Practices in Pluripotency Testing for Disease Models

As iPSC disease models become increasingly sophisticated through CRISPR genome editing, organoid development, and single-cell analysis, comprehensive iPSC quality control now extends beyond pluripotency markers alone. Researchers increasingly evaluate pluripotency, genomic stability, and lineage-specific differentiation potential as part of a broader validation strategy. Introduction The power of human induced pluripotent stem cells (iPSCs) lies in their ability to self-renew indefinitely and differentiate into any cell type of the human body. These properties make iPSCs indispensable for disease modelling, drug discovery, regenerative medicine, and cell-therapy development. However, the “pluripotent” label comes with a critical caveat: without rigorous testing of pluripotency (identity, potency, functionality), downstream experiments and therapies risk yielding unreliable or unsafe results. In this article, we explore the spectrum of methods for assessing pluripotency in iPSCs, compare their advantages and limitations, and highlight how implementing robust testing workflows can safeguard the quality of your iPSC-derived models and therapeutic products. Download iPS Cells tech note : Precision CRISPR Editing of Induced Pluripotent Stem (iPS) Cells

Read More
Scaling Cell Culture with Argo Automation: How EditCo Delivers High-Throughput Precision
Editing Process

Scaling Cell Culture with Argo Automation: How EditCo Delivers High-Throughput Precision

Delivering high-quality, precisely edited cells requires more than just cutting-edge CRISPR technology—it begins with a strong foundation in cell culture. Meet Argo: The Backbone of EditCo’s Automated Cell Culture Named after the legendary ship that carried Jason and the Argonauts, Argo represents our modern-day vessel for scientific exploration. Housed in a sterile enclosure, Argo is the backbone of our cell culture operations, built for high-throughput expansion, refeeding, and imaging of both immortalized and induced pluripotent stem (iPS) cells . Figure 1. Photo of the Argo workcell.

Read More